Human endogenous retrovirus epitope (HERV epitope)

Human endogenous retrovirus (HERV) epitopes are antigenic sequences derived from ancient retroviral DNA that has been integrated into the human germline over millions of years. Although these elements comprise nearly 8% of the human genome and are typically silenced by epigenetic mechanisms, they can be reactivated by environmental stressors, inflammatory cytokines, or other viral infections. Upon reactivation, HERV genes express proteins such as Env (envelope), Gag (capsid), and Pol (polymerase), which serve as potent immunogens. In autoimmune and neurodegenerative diseases like multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), certain HERV proteins (e.g., HERV-W Env, HERV-K Env) act as pro-inflammatory triggers that drive neurotoxicity and demyelination. In oncology, HERV epitopes are frequently overexpressed in various malignancies, functioning as tumor-associated antigens (TAAs) that can be exploited for targeted immunotherapy. Current drug development efforts focus on neutralizing antibodies to block HERV-mediated inflammation and vaccine-based approaches to eliminate HERV-positive cancer cells.

Other names

Human endogenous retrovirus antigenHERV antigenHERV-derived epitopeEndogenous retroviral peptideHERV-K envelope proteinHERV-W envelope protein

Monoclonal antibodies neutralize specific HERV envelope proteins to prevent pro-inflammatory receptor activation (e.g., TLR4), while vaccines and adoptive cell therapies (CAR-T) induce cytotoxic immune responses against cells expressing HERV-derived peptides on their surface.